Drug Search Results
More Filters [+]

CZ-48

Alternative Names: cz-48, cz48, cz 48
Latest Update: 2023-01-23
Latest Update Note: News Article

Product Description

Our lead drug candidate, CZ48, is an improved form of the drug 9-NitroCamptothecin (9NC)Ê. CZ48 has been designed to significantly improve blood levels compared to 9NC,, yet retain this high degree of anti-cancer activity. In vitro studies show that when CZ48 is incubated with Human Serum Albumin (HSA), blood levels of active drug are increased more than tenfold compared to 9NC. This increase in drug availability should translate into an even higher degree of efficacy. (Sourced from: http://www.caopharmaceuticals.com/lead-drug.html)

Mechanisms of Action: SARM Activator,CD38 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cao
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CZ-48

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CZ48

P1

Unknown status

Lymphoma

2019-10-01

41%

INST CZ48-01

P1

Completed

Lymphoma

2012-12-01

Recent News Events